Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 31, 2005. The report details a specific corporate action regarding the repurchase of the company's own shares in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2004.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 820,000 Ordinary shares of 25 pence each.
- Purchase Date: March 31, 2005.
- Price Per Share: 1,217.1166 pence.
- Treasury Shares Held: 86,338,000 (post-transaction).
- Shares in Issue: 5,854,074,743 (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company increased its Treasury share holdings by 820,000 shares. No other material changes to operations or financial position are disclosed in this specific text.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 820,000 share repurchase against the disclosed price of 1,217.1166 pence per share.
- Confirm the updated total share count (5,854,074,743 in issue) against subsequent filings.
- Review the full Annual Report (Form 20-F) for comprehensive financial performance data not included in this 6-K.